- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01805245
Mindfulness: a Novel Approach for the Management of Diabetes-related Distress
April 17, 2017 updated by: University of North Carolina, Chapel Hill
The purpose of this study is to evaluate the impact of stress reduction on physiological and psychological variables in adults with Type 2 diabetes (T2DM) who have moderate to severe levels of diabetes-related emotional distress.
Subjects will be randomized to one of two interventions.
We will evaluate the impact of the interventions on glucose metabolism, blood pressure, diabetes-related distress and quality of life.
Additionally, we will investigate the role of neuroendocrine dysfunction, systemic inflammation and diabetes self-care practices as mediators in the relationship between increased stress, adverse glucose metabolism and elevated blood pressure in those subjects with T2DM.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
78
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 30 years
- Male or female
- Duration of diabetes 1-15 years from time of initial diagnosis
- Diagnosis of T2DM made/confirmed by physician
- Completed diabetes education in the past
- Most recent HgA1c >7%; measurement must be within the past 6 months either in physicians office or at the Thriving with Diabetes Boot Camp Class
Treatment for diabetes must include any or all of the following modalities:
diet, exercise, oral medications, insulin or other injectable diabetic medication
- Score > 30 on the Problem Area in Diabetes (PAID) Questionnaire
- Able to use a glucometer for self-monitoring of blood glucose values
- Most recent clinic blood pressure less than 180/95
Exclusion Criteria:
- History of ketoacidosis
- Age at diagnosis of T2DM < 30 years
- Score >15 on the PHQ-9
- Previous training in relaxation or meditation techniques
- Current practice of yoga, tai chi or any other mind-body movement for > 60 minutes per week
- Current use of a psychoactive drug for less than 3 months or not yet on a stable dose
- Inability to participate fully or behave appropriately in the group treatment setting, as observed by baseline acknowledgement of substance abuse, psychotic episode(s), psychiatric hospitalization or history of self- harm within the past 2 years, or current suicidal or homicidal ideation
- Inability to complete standardized instruments because of a cognitive deficit or language barrier
- Current use or use within the past 3 months of oral glucocorticoids, excluding intraocular, topical or inhaled preparations
- History of inflammatory diseases including rheumatoid arthritis and inflammatory bowel disease
- Use of immune modulating agents
- Night shift work or other type of schedule in which sleep wake cycle is disrupted
- Women who consume > 7 alcoholic drinks per week and men who consume > 14 drinks per week
- Current use or history of daily tobacco use within the past 1 year
- End stage renal failure on dialysis
- Pregnancy or post partum <3 months
- Subjects with known secondary causes of hypertension including renal artery stenosis, pheochromocytoma, coarctation of aorta, hyperaldosteronemia
- Non-dominant arm circumference > 46cm
- Unwilling to accept randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mindfulness Based Stress Reduction
|
Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
|
Active Comparator: Health Education Control
|
Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HgA1c
Time Frame: 0,8,24 weeks
|
We will assess change in glycemic control using the A1c.
It will be measured at baseline, immediately following the 8 week intervention and at 24 weeks from baseline.
|
0,8,24 weeks
|
Diabetes Distress
Time Frame: 0,8,24 weeks
|
The Problem Areas in Diabetes will be used to assess the change in diabetes emotional distress at baseline, immediately following the 8 week intervention and at 24 weeks from baseline
|
0,8,24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SF36 Physical Health Score
Time Frame: 0, 8,24 weeks
|
This measure is a patient reported outcome assessing general quality of life and will be assessed using the standardized SF36 tool.
|
0, 8,24 weeks
|
SF36 Mental Health Score
Time Frame: 0,8,24 weeks
|
This measure is a patient reported outcome assessing general quality of life and will be assessed using the standardized SF36 tool.
|
0,8,24 weeks
|
Mean 24 hour ambulatory systolic blood pressure
Time Frame: 0,8,24 weeks
|
Mean systolic blood pressure over 24 hours.
|
0,8,24 weeks
|
Mean 24 hour diastolic ambulatory blood pressure
Time Frame: 0,8,24 weeks
|
Mean diastolic blood pressure over 24 hours
|
0,8,24 weeks
|
HOMA-IR
Time Frame: 0,8,24 weeks
|
For those participants that are not using insulin, we will assess the degree of insulin resistance using the HOMA-IR, which is derived from the fasting insulin and fasting glucose.
|
0,8,24 weeks
|
Depression
Time Frame: 0,8,24 weeks
|
Using the Beck Depression Inventory we will assess symptoms of depression using this standardized patient reported outcome.
|
0,8,24 weeks
|
State Anxiety
Time Frame: 0,8,24 weeks
|
Using the State and Trait Anxiety Assessment we will measure "state" anxiety.
|
0,8,24 weeks
|
Trait Anxiety
Time Frame: 0,8,24 weeks
|
Using the State and Trait Anxiety Survey we will assess "trait" anxiety.
|
0,8,24 weeks
|
Social Support
Time Frame: 0,8,24 weeks
|
Using the Duke Social Support and Stress Scale we will assess the degree of social support participants report in their lives.
|
0,8,24 weeks
|
Coping Style
Time Frame: 0,8,24 weeks
|
Using the Coping Orientation to Problems Experienced Scale, we will evaluate the various coping styles and how they may change over time.
|
0,8,24 weeks
|
General Stress
Time Frame: 0,8,24 weeks
|
Using the Perceived Stress Scale we will assess general life stressors.
|
0,8,24 weeks
|
Cortisol 24 hour area under the curve
Time Frame: 0,8,24 weeks
|
Calculating the area under the curve for 24 hours we will assess cortisol secretion as a physiological assessment of stress
|
0,8,24 weeks
|
Cortisol Awakening Response
Time Frame: 0,8,24 weeks
|
We will measure the cortisol awakening response using measures of cortisol prior to arising and 30 minutes after waking up.
|
0,8,24 weeks
|
IL-6
Time Frame: 0,8, 24 weeks
|
IL-6 is an assessment of systemic inflammation and will be measured in serum.
|
0,8, 24 weeks
|
Summary of Diabetes Self-Care Activities
Time Frame: 0,8,24 weeks
|
This patient reported measure assesses the frequency which participants engage in self-care activities that are critical for DM self-management.
|
0,8,24 weeks
|
Average 24 hour glucose by continuous glucose monitor (cgm)
Time Frame: 0,8,24 weeks
|
Average cgm glucose over 24 hours
|
0,8,24 weeks
|
Average night time glucose
Time Frame: 0,8,24 weeks
|
Average night time glucose from 10pm-6am using continuous glucose monitoring values
|
0,8,24 weeks
|
Average day time glucose
Time Frame: 0,8,24 weeks
|
Average day time glucose from 6am-10pm using continuous glucose monitoring values
|
0,8,24 weeks
|
Block Food Frequency Questionnaire
Time Frame: Week 0
|
Standardized assessment of dietary patterns
|
Week 0
|
Mean Day Systolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
|
The average systolic blood pressure measured by ambulatory blood pressure monitoring between 6 am and 10 pm
|
0,8,24 weeks
|
Mean Day Diastolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
|
The average systolic blood pressure measured by ambulatory blood pressure monitoring between 6 am and 10 pm
|
0,8,24 weeks
|
Mean Night Systolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
|
The average systolic blood pressure measured by ambulatory blood pressure monitoring between 10 pm and 6 am.
|
0,8,24 weeks
|
Mean Night Diastolic Ambulatory Blood Pressure
Time Frame: 0,8,24 weeks
|
The average diastolic blood pressure measured by ambulatory blood pressure monitoring between 10 pm and 6 am.
|
0,8,24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mindfulness
Time Frame: 0,8,24 weeks
|
To assess mindfulness we will utilize the Five Facet Mindfulness Questionnaire.
|
0,8,24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Laura A Young, MD, PhD, University of North Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2012
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
December 1, 2015
Study Registration Dates
First Submitted
June 15, 2012
First Submitted That Met QC Criteria
March 4, 2013
First Posted (Estimate)
March 6, 2013
Study Record Updates
Last Update Posted (Actual)
April 19, 2017
Last Update Submitted That Met QC Criteria
April 17, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-0333
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
University of PadovaRecruitingStress | Stress Disorder | Work Related StressItaly
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...Enrolling by invitationStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
Duquesne UniversityUniversity of California, San Diego; West Penn Allegheny Health System; El Centro... and other collaboratorsTerminated
-
University of Sao PauloCompleted
-
Syracuse VA Medical CenterUS Department of Veterans AffairsCompletedEmotional Stress | Psychological Stress | Life StressUnited States
-
Dana-Farber Cancer InstituteEnrolling by invitationStress | Post Traumatic Stress Disorder | Work Related StressUnited States
-
Royal Cornwall Hospitals TrustEnrolling by invitationStress | Stress, Psychological | Stress, JobUnited Kingdom
-
Taichung Veterans General HospitalUnknown
-
Northumbria UniversityVolac International LtdNot yet recruitingStress | Mood | Physiological Stress
Clinical Trials on Mindfulness Based Stress Reduction
-
Duke UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedCardiovascular Diseases | Inflammation | Stress, Psychological | SleepUnited States
-
University of California, San FranciscoCompletedDementia | Frontotemporal Dementia | Frontotemporal Lobar Degeneration | Caregiver Stress Syndrome | Caregiver Burnout | Dementia Frontal | Mindfulness Based Stress ReductionUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruiting
-
Oregon Health and Science UniversityPortland VA Medical CenterCompleted
-
Chang Gung Memorial HospitalRecruitingLate Life DepressionTaiwan
-
Schneider Children's Medical Center, IsraelCompletedInflammatory Bowel DiseasesIsrael
-
Clemson UniversityUniversity of California, Los Angeles; Prisma Health-UpstateCompletedQuality of Life | Diabetes | Stress | Health Behavior | Pre-DiabetesUnited States
-
University of AarhusVU University of AmsterdamUnknown
-
Johns Hopkins UniversityCompleted
-
Spaulding Rehabilitation HospitalCompletedStress | Brain Injury | Traumatic Brain InjuryUnited States